Renovorx Stock Performance

RNXT Stock  USD 0.99  0.04  4.21%   
RenovoRx has a performance score of 2 on a scale of 0 to 100. The company holds a Beta of 2.41, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, RenovoRx will likely underperform. RenovoRx right now holds a risk of 5.8%. Please check RenovoRx potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to decide if RenovoRx will be following its historical price patterns.

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in RenovoRx are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, RenovoRx may actually be approaching a critical reversion point that can send shares even higher in March 2026. ...more
1
Acquisition by Spiegel Robert J. of 25099 shares of RenovoRx at 1.02 subject to Rule 16b-3
11/11/2025
2
RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotechBio-Solutions Virtual Showcase on November 20th
11/19/2025
3
Acquisition by Agah Ramtin of 10000 shares of RenovoRx at 0.96 subject to Rule 16b-3
12/05/2025
4
Acquisition by Agah Ramtin of 12000 shares of RenovoRx at 0.85 subject to Rule 16b-3
12/16/2025
5
Acquisition by Shaun Bagai of 5000 shares of RenovoRx at 0.8524 subject to Rule 16b-3
12/17/2025
6
Shaun Bagai buys RenovoRx shares worth 4506 - Investing.com
12/22/2025
7
Acquisition by Agah Ramtin of 205 shares of RenovoRx at 0.826 subject to Rule 16b-3
12/30/2025
8
Acquisition by Agah Ramtin of 9795 shares of RenovoRx at 0.86 subject to Rule 16b-3
12/31/2025
9
The 170B Survival Race Why Big Pharma is Snapping Up Late-Stage Cancer Tech
01/08/2026
10
Jobs Data Is RenovoRx Inc stock a value trap - Trade Volume Summary Real-Time Volume Triggers - baoquankhu1.vn
01/16/2026
11
Acquisition by Agah Ramtin of 10000 shares of RenovoRx at 0.9975 subject to Rule 16b-3
01/21/2026
12
RenovoRx, Inc. Is Expected To Breakeven In The Near Future
01/28/2026
13
Acquisition by Marton Laurence of 25438 shares of RenovoRx at 1.7 subject to Rule 16b-3
02/02/2026
14
RenovoRx Announces Clinical Data Supporting the TAMP Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
02/04/2026
15
RenovoRx, Inc. Announces Change of Principal Accounting Officer - marketscreener.com
02/06/2026
Begin Period Cash Flow1.2 M
Total Cashflows From Investing Activities-12 K

RenovoRx Relative Risk vs. Return Landscape

If you would invest  100.00  in RenovoRx on November 9, 2025 and sell it today you would lose (1.00) from holding RenovoRx or give up 1.0% of portfolio value over 90 days. RenovoRx is currently generating 0.1541% in daily expected returns and assumes 5.8008% risk (volatility on return distribution) over the 90 days horizon. In different words, 52% of stocks are less volatile than RenovoRx, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days RenovoRx is expected to generate 7.08 times more return on investment than the market. However, the company is 7.08 times more volatile than its market benchmark. It trades about 0.03 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.12 per unit of risk.

RenovoRx Target Price Odds to finish over Current Price

The tendency of RenovoRx Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.99 90 days 0.99 
about 29.24
Based on a normal probability distribution, the odds of RenovoRx to move above the current price in 90 days from now is about 29.24 (This RenovoRx probability density function shows the probability of RenovoRx Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.41 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, RenovoRx will likely underperform. Additionally RenovoRx has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   RenovoRx Price Density   
       Price  

Predictive Modules for RenovoRx

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as RenovoRx. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of RenovoRx's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.050.996.79
Details
Intrinsic
Valuation
LowRealHigh
0.112.218.01
Details
Naive
Forecast
LowNextHigh
0.020.906.70
Details
4 Analysts
Consensus
LowTargetHigh
5.516.056.72
Details

RenovoRx Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. RenovoRx is not an exception. The market had few large corrections towards the RenovoRx's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold RenovoRx, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of RenovoRx within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.18
β
Beta against Dow Jones2.41
σ
Overall volatility
0.09
Ir
Information ratio -0.01

RenovoRx Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of RenovoRx for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for RenovoRx can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
RenovoRx had very high historical volatility over the last 90 days
RenovoRx has some characteristics of a very speculative penny stock
The company reported the previous year's revenue of 43 K. Net Loss for the year was (8.81 M) with profit before overhead, payroll, taxes, and interest of 629 K.
RenovoRx currently holds about 10.77 M in cash with (9.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
RenovoRx has a poor financial position based on the latest SEC disclosures
Latest headline from news.google.com: RenovoRx, Inc. Announces Change of Principal Accounting Officer - marketscreener.com

RenovoRx Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of RenovoRx Stock often depends not only on the future outlook of the current and potential RenovoRx's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. RenovoRx's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding23.6 M
Cash And Short Term Investments7.2 M

RenovoRx Fundamentals Growth

RenovoRx Stock prices reflect investors' perceptions of the future prospects and financial health of RenovoRx, and RenovoRx fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on RenovoRx Stock performance.

About RenovoRx Performance

Assessing RenovoRx's fundamental ratios provides investors with valuable insights into RenovoRx's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the RenovoRx is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Tangible Assets(1.25)(1.31)
Return On Capital Employed(2.03)(2.13)
Return On Assets(1.25)(1.31)
Return On Equity(1.77)(1.68)

Things to note about RenovoRx performance evaluation

Checking the ongoing alerts about RenovoRx for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for RenovoRx help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
RenovoRx had very high historical volatility over the last 90 days
RenovoRx has some characteristics of a very speculative penny stock
The company reported the previous year's revenue of 43 K. Net Loss for the year was (8.81 M) with profit before overhead, payroll, taxes, and interest of 629 K.
RenovoRx currently holds about 10.77 M in cash with (9.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
RenovoRx has a poor financial position based on the latest SEC disclosures
Latest headline from news.google.com: RenovoRx, Inc. Announces Change of Principal Accounting Officer - marketscreener.com
Evaluating RenovoRx's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate RenovoRx's stock performance include:
  • Analyzing RenovoRx's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether RenovoRx's stock is overvalued or undervalued compared to its peers.
  • Examining RenovoRx's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating RenovoRx's management team can have a significant impact on its success or failure. Reviewing the track record and experience of RenovoRx's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of RenovoRx's stock. These opinions can provide insight into RenovoRx's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating RenovoRx's stock performance is not an exact science, and many factors can impact RenovoRx's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for RenovoRx Stock Analysis

When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.